A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

NCT07728383 · tracked via the Priya Life Science USA tracker

Sponsor

Gila Therapeutics, Inc.

Phase

Phase 4

Started

2026-06-17

Last updated

2026-07-27

Condition(s) studied

Obesity & Overweight

Investigational drug(s) / intervention(s)

Semaglutide 6 mg liquid emulsion formulationWegovy® (semaglutide) TabletPlacebo liquid emulsion formulation

Semaglutide 6 mg liquid emulsion formulation: Semaglutide 6 mg liquid emulsion formulation daily

Wegovy® (semaglutide) Tablet: Wegovy® (semaglutide) Tablet 25 mg daily

Placebo liquid emulsion formulation: Placebo liquid emulsion formulation daily

Study summary

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Body Mass Index 30 to 45 Exclusion Criteria: * Type 2 Diabetes Mellitus * Multiple Endocrine Neoplasia Type 2 * Medullary thyroid cancer

Primary outcome measure(s)

Percent body weight change from baseline — 24 weeks
Percentage change in body weight at 24 weeks from baseline by calibrated scale.

Trial sites (1)

Facility	City	Region	Status
Clinical Research Institute of Minnesota	Minneapolis	Minnesota	Recruiting

Other trials for the same condition

Evaluation of a Mobile Wellness Application and Wearable Fitness Tracker on Weight Management and Health Outcomes Starting soon

Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults Starting soon

Fuzzle System for Appetite Control and Weight Management Starting soon

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study Starting soon

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07728383 on ClinicalTrials.gov ↗ ← All trials in the USA